Dopaminergic Neuronal Loss, Reduced Neurite Complexity and Autophagic Abnormalities in Transgenic Mice Expressing G2019S Mutant LRRK2
Open accessThe DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Abstract
Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene cause late-onset, autosomal dominant familial Parkinson's disease (PD) and also contribute to idiopathic PD. LRRK2 mutations represent the most common cause of PD with clinical and neurochemical features that are largely indistinguishable from idiopathic disease. Currently, transgenic mice expressing wild-type or disease-causing mutants of LRRK2 have failed to produce overt neurodegeneration, although abnormalities in nigrostriatal dopaminergic neurotransmission have been observed. Here, we describe the development and characterization of transgenic mice expressing human LRRK2 bearing the familial PD mutations, R1441C and G2019S. Our study demonstrates that expression of G2019S mutant LRRK2 induces the degeneration of nigrostriatal pathway dopaminergic neurons in an age-dependent manner. In addition, we observe autophagic and mitochondrial abnormalities in the brains of aged G2019S LRRK2 mice and markedly reduced neurite complexity of cultured dopaminergic neurons. These new LRRK2 transgenic mice will provide important tools for understanding the mechanism(s) through which familial mutations precipitate neuronal degeneration and PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![Figure 4 HPLC analysis of dopamine and its metabolites in G2019S LRRK2 transgenic mice. A–D, Levels of (A) dopamine (DA) and its metabolites, (B) DOPAC and (C) HVA, and (D) dopamine turnover ([DOPAC+HVA]/DA) in the striatum, olfactory bulb and cerebral cortex of 14–15 month-old G2019S LRRK2 TG mice (line 340) and their NTG littermates by HPLC analysis (n = 8/genotype). Bars present the mean ± SEM. *P<0.05 or **P<0.005 comparing TG with NTG as indicated.](https://figures.cochat.ai/paper-figures/2d21c616818941c89c421afafe071ad7/dopaminergic-neuronal-loss-reduced-neurite-complexity-and-autophagic-figure-4.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Dysregulated autophagy has also been associated with the expression of dominant mutants of LRRK2 (leucine‐rich repeat kinase 2) (Ramonet et al, 2011), the most common cause of familial PD.”
From Autophagy in major human diseases (2021) · cites this paper as Ramonet et al, 2011
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology
Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R. J., Calne, D. B., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.11.005 · Cited by 3,005 · cited 2×
“LRRK2-linked PD is characterized by the degeneration of substantia nigra dopaminergic neurons and gliosis together with heterogeneous protein inclusion pathology [3,10].”
BackgroundCloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease
Paisán-Ruı́z, C., Jain, S., Evans, E. W., Gilks, W. P., Simón, J., van der Brug, M., de Munain, A. L., Aparicio, S., Gil, A. M., Khan, N., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.10.023 · Cited by 2,405
Masliah, E., Rockenstein, E., Veinbergs, I., Mallory, M., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A., & Mucke, L. (2000) · Science · doi:10.1126/science.287.5456.1265 · Cited by 1,765
OPA1 Controls Apoptotic Cristae Remodeling Independently from Mitochondrial Fusion
Frezza, C., Cipolat, S., Martins de Brito, O., Micaroni, M., Beznoussenko, G. V., Rudka, T., Bartoli, D., Polishuck, R. S., Danial, N. N., De Strooper, B., et al. (2006) · Cell · doi:10.1016/j.cell.2006.06.025 · Cited by 1,673 · cited 1×
“area was determined for LRRK2 transgenic (TG) and non-transgenic (NTG) mice. Mitochondria were subclassified as either morphologically normal (class I), damaged (class II) or abnormally condensed/aggregated based upon previously established criteria (”
Healy, D. G., Falchi, M., O'Sullivan, S. S., Bonifati, V., Durr, A., Bressman, S., Brice, A., Aasly, J., Zabetian, C. P., Goldwurm, S., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70117-0 · Cited by 1,425 · cited 1×
“-linked families, including the R1441C/G/H, Y1699C, G2019S and I2020T variants”
BackgroundParkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity
West, A. B., Moore, D. J., Biskup, S., Bugayenko, A., Smith, W. W., Ross, C. A., Dawson, V. L., & Dawson, T. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507360102 · Cited by 1,228 · cited 1×
“1-LRRK2-Myc-His vector [18] was previously modified to introduce a 59 Kozak sequence and 39 stop codon (TAA) between flanking NheI sites.”
Self-citationNew stereological methods for counting neurons
West, M. J. (1993) · Neurobiology of Aging · doi:10.1016/0197-4580(93)90112-o · Cited by 940 · cited 1×
“Unbiased stereological methodology was employed as described previously [55,56] to count TH+ and Nissl+ neurons in the left and right pars compacta region of every fourth section throughout the ventral midbrain.”
MethodA common LRRK2 mutation in idiopathic Parkinson's disease
Gilks, W. P., Abou-Sleiman, P. M., Gandhi, S., Jain, S., Singleton, A., Lees, A. J., Shaw, K., Bhatia, K. P., Bonifati, V., Quinn, N. P., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17830-1 · Cited by 774 · cited 1×
“. Of these, G2019S is the most common variant that uniquely contributes to both familial and sporadic PD”
BackgroundKinase activity is required for the toxic effects of mutant LRRK2/dardarin
Greggio, E., Jain, S., Kingsbury, A., Bandopadhyay, R., Lewis, P., Kaganovich, A., van der Brug, M. P., Beilina, A., Blackinton, J., Thomas, K. J., et al. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.04.001 · Cited by 671 · cited 1×
“LRRK2-induced neuronal toxicity in vitro in a GTP-binding- and kinase-dependent manner [13,19-22], suggesting a gain-of-function mechanism for familial mutations.”
BackgroundLRRK2 G2019S as a Cause of Parkinson's Disease in Ashkenazi Jews
Ozelius, L. J., Senthil, G., Saunders-Pullman, R., Ohmann, E., Deligtisch, A., Tagliati, M., Hunt, A. L., Klein, C., Henick, B., Hailpern, S. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmc055509 · Cited by 665
Cited by
Items 201–300 of 406
Han, M., Lee, E.-H., & Koh, S. (2016) · International Neurourology Journal · doi:10.5213/inj.1632776.388 · Cited by 35
“stem cells from PD patients harboring the LRRK2-G2019S mutation and human LRRK2-G2019S-expressing transgenic mice [65-67].”
BackgroundEndosomal sorting pathways in the pathogenesis of Parkinson's disease
(2020) · Progress in Brain Research · doi:10.1016/bs.pbr.2020.02.001 · Cited by 25
Self-citationCompartmentalized Signaling in Aging and Neurodegeneration
Benedetto, G. D., Iannucci, L. F., Surdo, N. C., Zanin, S., Conca, F., Grisan, F., Gerbino, A., & Lefkimmiatis, K. (2021) · Cells · doi:10.3390/cells10020464 · Cited by 30
The Upshot of LRRK2 Inhibition to Parkinson’s Disease Paradigm
Esteves, A. R., G-Fernandes, M., Santos, D., Januário, C., & Cardoso, S. M. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8980-6 · Cited by 33
“G2019S LRRK2) induces an accumulation of autophagic vesicles [56] and lysosomal inclusions [57], which could be due to an interaction with Rab7 [58].”
BackgroundConvergent pathways in Parkinson’s disease
Cherubini, M., & Wade‐Martins, R. (2017) · Cell and Tissue Research · doi:10.1007/s00441-017-2700-2 · Cited by 31
“Recent findings have shown that two of the most frequent mutations of LRRK2,G2019S and R1441C, result in progressive degeneration of dopaminergic neurons due to the accumulation of autophagic vacuoles and increased mitochondrial autophagy (Ramonet et al. 2011).”
BackgroundNeuronal microtubules and proteins linked to Parkinson’s disease: a relevant interaction?
Calogero, A. M., Mazzetti, S., Pezzoli, G., & Cappelletti, G. (2019) · Biological Chemistry · doi:10.1515/hsz-2019-0142 · Cited by 32
Bono, F., Mutti, V., Devoto, P., Bolognin, S., Schwamborn, J. C., Missale, C., & Fiorentini, C. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.12.001 · Cited by 29
Macroautophagy and Mitophagy in Neurodegenerative Disorders: Focus on Therapeutic Interventions
Magalhães, J. D., Fão, L., Vilaça, R., Cardoso, S. M., & Rego, A. C. (2021) · Biomedicines · doi:10.3390/biomedicines9111625 · Cited by 30
“Moreover, in mice carrying mutant G2019S LRRK2, there was an increment of early and late autophagic vesicles, with detrimental effects on the number of neurons bearing tyrosine hydroxylase (TH) and on cortex neuronal morphology [201].”
BackgroundLangston, R. G., Rudenko, I. N., & Cookson, M. (2016) · Biochemical Journal · doi:10.1042/bj20150985 · Cited by 29
[Chronic blepharoconjunctivitis during a treatment with acitretin (Soriatane)].
Denis, P., Nordmann, J. –., Saïag, P., Liotet, S., Laroche, L., & Saraux, H. (1993) · PubMed · Cited by 28
Leucine‐rich repeat kinase 2 and lysosomal dyshomeostasis in Parkinson disease
Cogo, S., Manzoni, C., Lewis, P. A., & Greggio, E. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14908 · Cited by 27
“2008) and then confirmed by studies performed in rat-derived neurons expressing mutant LRRK2, as well as idiopathic and LRRK2-PD induced pluripotent stem cells (iPSCs) (S anchez-Dan es et al. 2012; Ramonet et al. 2011; MacLeod et al. 2006).”
BackgroundResultShahaduzzaman, M., Acosta, S., Bickford, P. C., & Borlongan, C. V. (2013) · Medical Hypotheses · doi:10.1016/j.mehy.2013.07.025 · Cited by 27
“DA neurons within the substantia nigra pars compacta in an agedependent manner [41].”
BackgroundWhat lysosomes actually tell us about Parkinson’s disease?
Bourdenx, M., & Dehay, B. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.02.008 · Cited by 26
Tozzi, A., Durante, V., Bastioli, G., Mazzocchetti, P., Novello, S., Mechelli, A., Morari, M., Costa, C., Mancini, A., Filippo, M. D., et al. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.06.008 · Cited by 27
LRRK2 and autophagy: a common pathway for disease
Manzoni, C. (2012) · Biochemical Society Transactions · doi:10.1042/bst20120126 · Cited by 31
Focus on the Small GTPase Rab1: A Key Player in the Pathogenesis of Parkinson’s Disease
Martínez‐Menárguez, J. A., Martínez‐Alonso, E., Cara‐Esteban, M., & Tomás, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222112087 · Cited by 26
“The G2019S mutation, the most common PD-related mutation that increases kinase activity, induces autophagy abnormalities and affects neurite development [206,207].”
BackgroundThe Role of LRRK2 in Intracellular Organelle Dynamics
Boecker, C. A. (2023) · Journal of Molecular Biology · doi:10.1016/j.jmb.2023.167998 · Cited by 27
The role of apolipoprotein E in neurodegeneration and cardiovascular disease
Lopez, M. F., Krastins, B., & Ning, M. (2014) · Expert Review of Proteomics · doi:10.1586/14789450.2014.901892 · Cited by 29
Schildt, A., Walker, M. D., Dinelle, K., Miao, Q., Schulzer, M., OʼKusky, J. R., Farrer, M. J., Doudet, D. J., & Sossi, V. (2018) · Journal of Parkinson s Disease · doi:10.3233/jpd-181446 · Cited by 24
“An age-dependent loss of DA neurons has been described in some LRRK2 G2019S transgenic mice [21, 22], but in similar rat models there have been no reports of a loss of DA neurons, with behavioral deficits also rare [23, 24].”
Imaging Leucine-Rich Repeat Kinase 2 In Vivo with 18F-Labeled Positron Emission Tomography Ligand
Chen, Z., Chen, J., Chen, L. M., Yoo, C., Rong, J., Fu, H., Shao, T., Coffman, K. J., Steyn, S. J., Davenport, A. T., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00551 · Cited by 23
Modulation of Neuronal Survival Factor MEF2 by Kinases in Parkinson’s Disease
Yin, Y., She, H., Li, W., Yang, Q., Guo, S., & Mao, Z. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00171 · Cited by 25
“It was found that overexpression of G2019S mutant LRRK2 in neuronal cells decreased neurite length and caused an accumulation of autophagic structures (MacLeod et al., 2006; Plowey et al., 2008; Ramonet et al., 2011).”
BackgroundDNA damage preceding dopamine neuron degeneration in A53T human α-synuclein transgenic mice
Wang, D., Yu, T., Liu, Y., Yan, J., Guo, Y., Jing, Y., Yang, X., Song, Y., & Tian, Y. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.11.008 · Cited by 25
Self-citationG2019s LRRK2 promotes mitochondrial fission and increases TNFα-mediated neuroinflammation responses
Ho, D. H., Lee, H., Son, I., & Seol, W. (2019) · Animal Cells and Systems · doi:10.1080/19768354.2019.1585948 · Cited by 23
“…for 30 min, followed by measurement using a Synergy 2 microplate reader (BioTek) at 450 nm. Animal care and preparation of brain lysates GS LRRK2 transgenic mice (Ramonet et al. 2011) were purchased from The Jackson Laboratory (strain B6; C3Tg [PDGFB-LRRK2*G2019S] 340D jmo/J, stock number 016575).”
BackgroundMethodCresto, N., Gaillard, M., Gardier, C., Gubinelli, F., Diguet, E., Bellet, D., Legroux, L., Mitja, J., Aurégan, G., Guillermier, M., et al. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104614 · Cited by 27
LRRK2 and Protein Aggregation in Parkinson’s Disease: Insights From Animal Models
Dues, D. J., & Moore, D. J. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00719 · Cited by 24
Self-citationAnimal Models of Parkinson’s Disease
Blesa, J., Trigo‐Damas, I., Quiroga‐Varela, A., & del Rey, N. L. (2016) · InTech eBooks · doi:10.5772/63328 · Cited by 31
LRRK2 and Proteostasis in Parkinson’s Disease
Pérez‐Carrión, M. D., Posadas, I., Solera, J., & Ceña, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126808 · Cited by 25
Targeting Mitochondria as a Therapeutic Approach for Parkinson’s Disease
Abrishamdar, M., Jalali, M. S., & Farbood, Y. (2022) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-022-01265-w · Cited by 25
Cellular effects of LRRK2 mutations
Cookson, M. (2012) · Biochemical Society Transactions · doi:10.1042/bst20120165 · Cited by 25
Mohamed, N., Larroquette, F., Beitel, L. K., Fon, E. A., & Durcan, T. M. (2019) · Journal of Parkinson s Disease · doi:10.3233/jpd-181515 · Cited by 26
Novel insights into the neurobiology underlying LRRK2-linked Parkinson's disease
Gómez‐Suaga, P., Fdez, E., Fernández, B., Martínez-Salvador, M., Ramírez, M. B., Madero‐Pérez, J., Rivero-Ríos, P., Fuentes, J. M., & Hilfiker, S. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.05.020 · Cited by 30
Transgenic Mouse Models for the Study of Neurodegenerative Diseases
Marín‐Moreno, A., Canoyra, S., Fernández‐Borges, N., Espinosa, J. C., & Torres, J. M. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2801021 · Cited by 22
Role of Autophagy in Parkinson’s Disease
Grace, G. Y., Zhang, C., & Lim, K. (2013) · InTech eBooks · doi:10.5772/54927 · Cited by 22
Early diagnosis and therapy of Parkinson’s disease: can disease progression be curbed?
Kansara, S. G., Trivedi, A., Chen, S., Jankovic, J. J., & Le, W. (2012) · Journal of Neural Transmission · doi:10.1007/s00702-012-0840-9 · Cited by 22
“…the cause of PD in North African Arabs and Ashkenazi Jews (Lesage et al. 2006; Ozelius et al. 2006) as a result of high pathogenic allele frequency, and has been reported to induce subtle dendrite degeneration, DA cell loss, and abnormal autophagic pathways (Lin et al. 2010; Ramonet et al. 2011).”
BackgroundMelachroinou, K., Λεάνδρου, Ε., Valkimadi, P., Memou, A., Hadjigeorgiou, G. M., Stefanis, L., & Rideout, H. J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0166053 · Cited by 21
Kritzinger, A., Ferger, B., Gillardon, F., Stierstorfer, B., Birk, G., Kochanek, S., & Ciossek, T. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.02.008 · Cited by 22
Impaired intracortical transmission in G2019S leucine rich‐repeat kinase Parkinson patients
Ponzo, V., Lorenzo, F. D., Brusa, L., Schirinzi, T., Battistini, S., Ricci, C., Sambucci, M., Caltagirone, C., & Koch, G. (2017) · Movement Disorders · doi:10.1002/mds.26931 · Cited by 19
“This pathological cascade is involved in the degeneration of nigro-striatal pathway dopaminergic neurons in an age-dependent manner.(5) Although much progress has been made, how LRRK2 affects synaptic transmission in PD patients is still poorly understood.”
BackgroundModeling LRRK2 Pathobiology in Parkinson’s Disease: From Yeast to Rodents
Daniel, G., & Moore, D. J. (2014) · Current topics in behavioral neurosciences · doi:10.1007/7854_2014_311 · Cited by 21
Self-citationKofoed, R. H., Betzer, C., Ferreira, N., & Jensen, P. H. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104720 · Cited by 20
Mancini, A., Mazzocchetti, P., Sciaccaluga, M., Megaro, A., Bellingacci, L., Beccano-Kelly, D. A., Filippo, M. D., Tozzi, A., & Calabresi, P. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00158 · Cited by 19
“Interestingly, even if there were no signs of neuronal loss in the midbrain, R1441C transgenic mice displayed an impairment of locomotor activity, which was related to the observed cortical involvement (Ramonet et al., 2011).”
BackgroundResultInfluentialTransgenic LRRK2 R 1441 G rats–a model for Parkinson disease?
Shaikh, K. T., Yang, A., Youshin, E., & Schmid, S. (2015) · PeerJ · doi:10.7717/peerj.945 · Cited by 19
“…an early symptom of PD. Similarly, other classic transgenic LRRK2 mouse models over-expressing mutant LRRK2 have mostly failed to show PD specific gross motor deficits (Li et al., 2009; Li et al., 2010; Melrose et al., 2010) despite mild nigral neurodegeneration (Ramonet et al., 2011).”
BackgroundMa, Q., Hu, Q., Xu, R., Zhen, X.-C., & Wang, G. (2015) · Acta Pharmacologica Sinica · doi:10.1038/aps.2015.48 · Cited by 20
Aufschnaiter, A., Kohler, V., Walter, C., Tosal-Castano, S., Habernig, L., Wolinski, H., Keller, W., Vögtle, F. ‐., & Büttner, S. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00205 · Cited by 20
“In line with studies reporting severe impairment of mitochondrial morphology upon expression of full-length LRRK2 or its pathogenic variants (Ramonet et al., 2011; Su and Qi, 2013), the yeast mitochondrial network appeared fragmented and aggregated upon LRRK2RCK expression (Figure 2B).”
BackgroundPrinciples of brain aging: Status and challenges of modeling human molecular changes in mice
Kluever, V., & Fornasiero, E. F. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101465 · Cited by 20
Lysosomal Pathogenesis of Parkinson's Disease: Insights From LRRK2 and GBA1 Rodent Models
Volta, M. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01290-z · Cited by 18
“An early study showed accumulation of autophagic vacuoles in cortex and striatum of G2019SLRRK2 and, to a lesser extent, R1441C-LRRK2 overexpressing mice, albeit in the absence of aSyn or Tau neuropathologies [82].”
BackgroundLee, J. H., Han, J., Joe, E.-H., & Jou, I. (2021) · Journal of Biomedical Science · doi:10.1186/s12929-021-00747-1 · Cited by 18
“Previous studies show that a LRRK2-GS mouse model exhibited a modest loss of dopaminergic neurons accompanied by accumulation of autophagosomes, mitochondrial alterations, and ER stress, revealing the direct toxic effect of LRRK2-GS on neurons [20, 39, 59].”
BackgroundDiscovery of LRRK2 inhibitors by using an ensemble of virtual screening methods
Gancia, E., de Groot, M. J., Burton, B., & Clark, D. E. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.03.098 · Cited by 17
Rideout, H. J., & Re, D. B. (2017) · Advances in Neurobiology · doi:10.1007/978-3-319-49969-7_10 · Cited by 17
Senchuk, M. M., Raamsdonk, J. M. V., & Moore, D. J. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105267 · Cited by 17
Self-citationLarijani, B. A., Goodarzi, P., Payab, M., Tayanloo-Beik, A., Sarvari, M., Gholami, M., Gilany, K., Nasli‐Esfahani, E., Yarahmadi, M., Ghaderi, F., et al. (2019) · Advances in experimental medicine and biology · doi:10.1007/5584_2019_422 · Cited by 19
Progressively disrupted somatodendritic morphology in dopamine neurons in a mouse Parkinson's model
Lynch, W. B., Tschumi, C. W., Sharpe, A. L., Branch, S. Y., Chen, C., Ge, G., Li, S., & Beckstead, M. J. (2018) · Movement Disorders · doi:10.1002/mds.27541 · Cited by 20
Pathogenic Aspects and Therapeutic Avenues of Autophagy in Parkinson’s Disease
Kinet, R., & Dehay, B. (2023) · Cells · doi:10.3390/cells12040621 · Cited by 15
Kim, J. J., Daadi, E. W., Oh, T. T., Daadi, E. S., & Daadi, M. M. (2022) · Genes · doi:10.3390/genes13111937 · Cited by 14
“When the connection between the SNpc and the dorsal striatum is lost, the ability to produce controlled movement becomes impaired.”
BackgroundInfluentialSelf-citationModeling Parkinson’s disease in LRRK2 rodents
Domenicale, C., Magnabosco, S., & Morari, M. (2023) · Neuronal Signaling · doi:10.1042/ns20220040 · Cited by 15
Novel approaches to counter protein aggregation pathology in Parkinson's disease
Stott, S., Wyse, R. K. H., & Brundin, P. (2019) · Progress in brain research · doi:10.1016/bs.pbr.2019.10.007 · Cited by 16
Human leucine-rich repeat kinase 1 and 2: intersecting or unrelated functions?
Civiero, L., & Bubacco, L. (2012) · Biochemical Society Transactions · doi:10.1042/bst20120123 · Cited by 16
Christensen, K. V., Hentzer, M., Oppermann, F. S., Elschenbroich, S., Acheson-Dossang, P., Thirstrup, K., Egebjerg, J., Williamson, D. S., & Smith, G. P. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/447946 · Cited by 14
Role of LRRK2 in axonal transport and Parkinson’s disease
Twellsieck, B., & Boecker, C. A. (2025) · Biochemical Journal · doi:10.1042/bcj20253133 · Cited by 8
“Since early work observed an accumulation of autophagosomes in cells expressing pathogenic LRRK2 mutations [122–124], several studies have proposed a role of LRRK2 in the autophagy–lysosome pathway [125–134].”
Aging, Parkinson’s Disease, and Models: What Are the Challenges?
Bellantuono, I., Mortiboys, H., Rocha, E. M., Chamoli, M., Chinta, S. J., Andersen, J. K., Wallis, R., Bézard, E., Goldberg, M., Greenamyre, T., et al. (2023) · doi:10.59368/agingbio.20230010 · Cited by 16
“The MitoPark mouse model, initially described in 2007, consists of a selective deletion in the mitochondrial transcription factor M (TFAM) within DAT-positive (DAT + ) neurons 156 .”
MethodCombining Gene Transfer and Nonhuman Primates to Better Understand and Treat Parkinson’s Disease
Lasbleiz, C., Mestre‐Francés, N., Devau, G., Luquín, M. R., Tenenbaum, L., Kremer, E. J., & Verdier, J. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00010 · Cited by 14
Klonarakis, M., Vos, M. D., Woo, E. K., Ralph, L. T., Thacker, J. S., & Gil‐Mohapel, J. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104541 · Cited by 15
Overview of Mouse Models of Parkinson's Disease
Bobela, W., Zheng, L., & Schneider, B. L. (2014) · Current Protocols in Mouse Biology · doi:10.1002/9780470942390.mo140092 · Cited by 14
“Ramonet et al. (2011) later reported a phenotype in transgenic LRRK2G2019S mice, which showed progressive nigrostriatal degeneration and mitochondrial abnormalities.”
BackgroundMind the Gap: LRRK2 Phenotypes in the Clinic vs. in Patient Cells
Goveas, L. M., Mutez, E., Chartier‐Harlin, M., & Taymans, J. (2021) · Cells · doi:10.3390/cells10050981 · Cited by 15
MicroRNAs regulating autophagy: opportunities in treating neurodegenerative diseases
Mohseni, M., Behzad, G., Farhadi, A., Behroozi, J., Mohseni, H., & Valipour, B. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1397106 · Cited by 14
“These mutations enhance LRRK2 kinase activity but impair autophagic degradation, resembling the effects of LRRK2 deficiency (Plowey Cherra et al., 2008; Ramonet et al., 2011).”
Plotegher, N., & Civiero, L. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.3588-12.2012 · Cited by 12
“Additionally, the common LRRK2 mutation G2019S is associated with accumulation of autophagic vacuoles (Ramonet et al., 2011).”
BackgroundCresto, N., Gardier, C., Gaillard, M., Gubinelli, F., Roost, P., Molina, D., Joséphine, C., Dufour, N., Aurégan, G., Guillermier, M., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136760 · Cited by 13
“, vectors derived from herpes simplex virus (HSV) or adenovirus) also transduce other cell types in the striatum [51,52].”
BackgroundAnimal Models of Parkinson's Disease
Dawson, V. L., & Dawson, T. M. (2025) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041644 · Cited by 12
Self-citationMonoamine Oxidase Inhibitors in Toxic Models of Parkinsonism
Бунеева, О. А., & Medvedev, A. E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031248 · Cited by 13
“These include transgenic animal models and viral vector models with the predominant use of mice or Drosophila melanogaster [15–19] or cell cultures [20–23].”
LRRK2 as a Potential Disease‐Modifying Target in Sporadic Parkinson's Disease
Lang, A. E., Hauser, R. A., Kalia, L. V., Hersh, B. P., Berger, Z., Arenas, R. L., Paisán‐Ruiz, C., Fraser, K. B., Jennings, D. L., Kluss, J. H., et al. (2025) · Movement Disorders · doi:10.1002/mds.70100 · Cited by 13
“109-111 Evidence for LRRK2 ’ s Role in Lysosomal Dysregulation in sPD Lysosomal dysfunction is associated with PD pathogenesis; several causal or PD-linked pathogenic variants (eg, GBA , LRRK2 , ATP13A2 , VPS35 , and RAB32 ) encode lysosomal, autophagic, and endosomal proteins.”
Insights into LRRK2 function and dysfunction from transgenic and knockout rodent models
Sloan, M., Alegre‐Abarrategui, J., & Wade‐Martins, R. (2012) · Biochemical Society Transactions · doi:10.1042/bst20120151 · Cited by 12
In silico comparative analysis of LRRK2 interactomes from brain, kidney and lung
Verma, A., Ebanks, K., Fok, C.-Y., Lewis, P. A., Bettencourt, C., & Bandopadhyay, R. (2021) · Brain Research · doi:10.1016/j.brainres.2021.147503 · Cited by 12
Domenicale, C., Mercatelli, D., Albanese, F., Novello, S., Vincenzi, F., Varani, K., & Morari, M. (2022) · Biomedicines · doi:10.3390/biomedicines10040881 · Cited by 11
“Only in 12–21-month-old mice overexpressing hG2019S under the PDGF promoter was a 18–50% neuronal loss in SNc consistently reported [21,22].”
BackgroundPET imaging in animal models of Parkinson’s disease
Ni, R. (2022) · Behavioural Brain Research · doi:10.1016/j.bbr.2022.114174 · Cited by 13
“[16], R1441G mutant LRRK2 endogenous LRRK2 promoter (BAC mice) [17].”
Human mini-brains for reconstituting central nervous system disorders
Kang, Y. J., Xue, Y., Shin, J. H., & Cho, H. (2023) · Lab on a Chip · doi:10.1039/d2lc00897a · Cited by 11
Translational approaches to restoring mitochondrial function in Parkinson's disease
Mortiboys, H., Macdonald, R., Payne, T., Sassani, M., Jenkins, T. M., & Bandmann, O. (2017) · FEBS Letters · doi:10.1002/1873-3468.12920 · Cited by 11
Role of rodent models in advancing precision medicine for Parkinson's disease
Simons, E., & Fleming, S. M. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-323-85555-6.00002-3 · Cited by 13
Jang, J., Oh, H., Nam, D., Seol, W., Seo, M. K., Park, S. W., Kim, H., Seo, H., Son, I., & Ho, D. H. (2018) · Animal Cells and Systems · doi:10.1080/19768354.2018.1518262 · Cited by 9
“…brain preparation G2019S TG mice were purchased from The Jackson Laboratory (strain B6; C3-Tg [PDGFB-LRRK2*G2019S] 340D jmo/J, stock number 016575) (Ramonet et al. 2011) and were housed in a specific pathogen-free facility at the Dankook University Animal Facility with the approval of the Dankook…”
BackgroundMethodSuzzi, S., Ahrendt, R., Hans, S., Semenova, S. A., Chekuru, A., Wirsching, P., Kroehne, V., Bilican, S., Sayed, S., Winkler, S., et al. (2021) · PLoS Genetics · doi:10.1371/journal.pgen.1009794 · Cited by 11
“Moreover, the monoamine signatures reported in the LRRK2 GOF mouse models are difficult to interpret, because they are not clearly linked to problems in either dopamine synthesis [12] or turnover [12,13].”
BackgroundIn Vitro Modeling of Leucine-Rich Repeat Kinase 2 G2019S-Mediated Parkinson's Disease Pathology
Vermilyea, S., & Emborg, M. E. (2018) · Stem Cells and Development · doi:10.1089/scd.2017.0286 · Cited by 9
“DAergic nigral cell loss has been observed in G2019S transgenic mice (3–5-fold increased expression) after 19–20 months, but not when examined after 1–2 months of age [54].”
BackgroundTaymans, J. (2014) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2014.915945 · Cited by 9
Cell-autonomous role of leucine-rich repeat kinase in the protection of dopaminergic neuron survival
Kang, J., Huang, G., Ma, L., Tong, Y., Shahapal, A., Chen, P., & Shen, J. (2023) · eLife · doi:10.7554/elife.92673 · Cited by 8
“…Li et al., 2010 ; Melrose et al., 2010 ; Daher et al., 2012 ; Tsika et al., 2014 ; Liu et al., 2015 ; Mikhail et al., 2015 ; Xiong et al., 2017 ), two studies reported that overexpression of LRRK2 G2019S but not R1441C resulted in DA neurodegeneration ( Ramonet et al., 2011 ; Xiong et al., 2018 ).”
BackgroundAlternative to LRRK2-IN-1 for Pharmacological Studies of Parkinson's Disease
Koshibu, K., van Asperen, J., Gerets, H. H. J., Garcia-Ladona, J., Lorthioir, O., & Courade, J. (2015) · Pharmacology · doi:10.1159/000439136 · Cited by 9
Mitochondrial Fission and Fusion
Hewitt, V. L., & Whitworth, A. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803783-6.00003-1 · Cited by 10
Neuronal death signaling pathways triggered by mutant LRRK2
Rideout, H. J. (2017) · Biochemical Society Transactions · doi:10.1042/bst20160256 · Cited by 9
Exploring the focal role of LRRK2 kinase in Parkinson’s disease
Kumar, S., Behl, T., Sehgal, A., Chigurupati, S., Singh, S., Mani, V., Aldubayan, M. A., Alhowail, A., Kaur, S., Bhatia, S., et al. (2022) · Environmental Science and Pollution Research · doi:10.1007/s11356-022-19082-5 · Cited by 10
“Staurosporine is a bacterium-derived natural indolinone component that inhibits a wide range of protein kinases by preventing adenosine triphosphate association to the kinase (Doggrell 2011; Ramonet et al. 2011).”
BackgroundParkinson's Disease: Leucine-Rich Repeat Kinase 2 and Autophagy, Intimate Enemies
Pedro, J. M. B., Gómez‐Sánchez, R., Pizarro‐Estrella, E., Niso‐Santano, M., González‐Polo, R. A., & Fuentes, J. M. (2012) · Parkinson s Disease · doi:10.1155/2012/151039 · Cited by 8
“The first indication of this possible interaction was the discovery that an endogenous part of LRRK2 is anchored to membranous structures of the cell, including the ER and endosomes [23], and that the overexpression of the mutant form of G2019S of LRRK2 in neuronal cells induces the accumulation of autophagic structur…”
BackgroundNguyen, A. P. T., Nguyen, L. T. N., Stokke, B. A., & Quinn, C. C. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1569733 · Cited by 7
Neuroglia in neurodegeneration: Alzheimer, Parkinson, and Huntington disease
Lim, D., Matute, C., Cavaliere, F., & Verkhratsky, A. (2025) · Handbook of Clinical Neurology · doi:10.1016/b978-0-443-19102-2.00012-0 · Cited by 8
Homozygous mutation of the LRRK2 ROC domain as a novel genetic model of parkinsonism
Chen, M., & Wu, R. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00844-9 · Cited by 9
“An investigation of the regulation of the tissue specificity of LRRK2 expression by autophagy showed the age-dependent accumulation of autophagic vacuoles in the cortex and striatum of R1441C and G2019S Tg mice, suggesting that LRRK2 expression is regulated by autophagy specifically in neuronal somas and axial process…”
BackgroundVaquero-Rodríguez, A., Razquin, J., Murueta‐Goyena, A., Miguélez, C., Ruíz-Ortega, J. Á., Lafuente, J. V., Bengoetxea, H., & Ortuzar, N. (2025) · Brain Structure and Function · doi:10.1007/s00429-025-02959-9 · Cited by 7
“…to α-syn-induced degeneration of DA neurons in this model, affecting the that report similar decreases at 3 weeks, with a progressive decline between 8 and 16 weeks post-injection (Li et al. 2009; Ramonet et al. 2011; Decressac et al. 2012), as well as in transgenic mice (Tagliaferro et al. 2015).”
Age- and Sex-Dependent Behavioral and Neurochemical Alterations in hLRRK2-G2019S BAC Mice
Yao, N., Skiteva, O., & Chergui, K. (2022) · Biomolecules · doi:10.3390/biom13010051 · Cited by 7
“Thus, aged mice overexpressing hG2019S under the PDGF-β promoter demonstrated a significant DA neuron loss [13,30].”
BackgroundGenetic Models of Parkinson’s Disease
Kachidian, P., & Gubellini, P. (2020) · Neuromethods · doi:10.1007/978-1-0716-0912-5_3 · Cited by 7
Pastic, A., Negeri, O., Ravel‐Chapuis, A., Savard, A., Trung, M. T., Palidwor, G., Guo, H., Marcogliese, P. C., Taylor, J. A., Okano, H., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.24.489327 · Cited by 7
Sitzia, G., Skiteva, O., & Chergui, K. (2022) · Biomolecules · doi:10.3390/biom12111635 · Cited by 5
“[25] demonstrated that mice expressing human LRRK2 harboring the G2019S mutation under the control of a CMV-enhanced human platelet-derived growth factor β-chain promoter, had unaltered horizontal and vertical locomotor activity at 6 and 15 months of age.”
BackgroundChanges in Liver Lipidomic Profile in G2019S-LRRK2 Mouse Model of Parkinson’s Disease
Nieto, Y. C., Yakhine-Diop, S. M. S., Moreno-Cruz, P., García, L. M., Pereira, A. G., Morales-Garcia, J. A., Niso‐Santano, M., González‐Polo, R. A., Uribe-Carretero, E., Durand, S., et al. (2023) · Cells · doi:10.3390/cells12050806 · Cited by 5
Mitochondrial dysfunction in Parkinson’s disease: a possible target for neuroprotection
Gleave, J. A., Perri, P. D., & Nash, J. E. (2014) · Frontiers in Biology · doi:10.1007/s11515-014-1337-8 · Cited by 5
Butzke, D., Dulisch, N., Dunst, S., Steinfath, M., Neves, M., Mathiak, B., & Grune, B. (2020) · doi:10.21203/rs.3.rs-16454/v1 · Cited by 6
“Reference abstract PMID 21494637 (20) was chosen because of respective inhouse knowledge regarding Parkinson’s disease gained during preparation of case studies for the AnimAltZEBET-database.”
BackgroundInfluentialParkinson's Disease Patient‐Specific Striatum Organoids Show Hallmarks of Increased Inflammation
Barmpa, K., Saraiva, C., Žagare, A., Tuzza, M., Longworth, J., Zuccoli, E., Hufnagel, K., Skwirblies, F., Schmidt, R., Brenner, D., et al. (2026) · Movement Disorders · doi:10.1002/mds.70176 · Cited by 4
Huang, L., Shimoji, M., Wang, J., Shah, S., Kamila, S., Biehl, E. R., Lim, S., Chang, A., Maguire‐Zeiss, K. A., Su, X., et al. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0208-3 · Cited by 6
“As reported by other investigators in different cell types [53–59], we also observed that the overexpression of LRRK2 G2019S results in shortened neuritic extensions.”
ResultAn, J., Yang, H., Park, S. M., Chwae, Y., & Joe, E.-H. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106528 · Cited by 6
“In aged (12 – 21 month) LRRK2-GS mice, tyrosine hydroxylase (TH)-immunoreactivity is progressively reduced in the substantia nigra and striatum (Chen et al., 2012; Chou et al., 2014; Ramonet et al., 2011; Yue et al., 2015).”
Metadata
- Authors
- Ramonet, D., Daher, J. P. L., Lin, B. M., Stafa, K., Kim, J., Banerjee, R., Westerlund, M., Pletnikova, O., Glauser, L., Yang, L., Liu, Y., Swing, D. A., Beal, M. F., Troncoso, J. C., McCaffery, J. M., Jenkins, N. A., Copeland, N. G., Galter, D., Thomas, B., Lee, M. K., Dawson, T. M., Dawson, V. L., & Moore, D. J.
- Affiliations
- École Polytechnique Fédérale de Lausanne (CH)
- Johns Hopkins University (US)
- University of Minnesota (US)
- Cornell University (US)
- Karolinska Institutet (SE)
- National Cancer Institute (US)
- Corresponding author
- Dawson, Valina L.
- Moore, Darren J.
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-04-06
- Volume
- 6
- Issue
- 4
- Pages
- e18568
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3071839
- OpenAlex
- W2166593844
- Cited by
- 405
- References
- 61
- Citations by year
- 2026: 11 · 2025: 15 · 2024: 8 · 2023: 14 · 2022: 23 · 2021: 27 · 2020: 31 · 2019: 28 · 2018: 33 · 2017: 32 · 2016: 27 · 2015: 27 · 2014: 39 · 2013: 36 · 2012: 44
- FWCI
- 26.20
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
- Funders
- National Science Foundation
- National Parkinson Foundation
- American Parkinson Disease Association
- Johns Hopkins University
- École Polytechnique Fédérale de Lausanne
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (127478)
- Vetenskapsrådet
- Parkinson Schweiz
- National Institutes of Health
- Parkinsonfonden
- National Institute of Neurological Disorders and Stroke (R01NS060885, NS060885, NS03877, P50NS038377, NS062165, R21NS062165)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- LRRK2, G2019S mutation, familial Parkinson's disease, transgenic mouse model, dopaminergic neuron loss, nigrostriatal pathway, neurite complexity, autophagy, mitochondrial abnormalities, age-related neurodegeneration
- MeSH terms
- Leucine-Rich Repeat Serine-Threonine Protein Kinase-2, Animals, Autophagy, Behavior, Animal, Chromatography, High Pressure Liquid, Dopamine, Humans, Mesencephalon, Mice, Transgenic, Motor Activity, Organ Culture Techniques, Neurites, Protein Serine-Threonine Kinases, Amino Acid Substitution, Protein Transport, Mutant Proteins, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.